Analyst Ratings for [APLS] Apellis Pharmaceuticals, Inc.

9/26/25	Downgrades	Neutral Sell	X
APLS Apellis Pharmaceuticals Goldman
$18
5/9/25	Downgrades	Buy Neutral	X
APLS Apellis Pharmaceuticals BofA Securities
$23
5/9/25	Downgrades	Strong Buy Outperform	X
APLS Apellis Pharmaceuticals Raymond James
$52
4/29/25	Initiated	Overweight	X
APLS Apellis Pharmaceuticals Cantor Fitzgerald
$44
12/17/24	Downgrades	Buy Neutral	X
APLS Apellis Pharmaceuticals Goldman
$36
11/21/24	Initiated	Equal-Weight	X
APLS Apellis Pharmaceuticals Morgan Stanley
$31
10/25/24	Initiated	Sector Perform	X
APLS Apellis Pharmaceuticals RBC Capital Mkts
$25
10/16/24	Initiated	Sector Outperform	X
APLS Apellis Pharmaceuticals Scotiabank
10/16/24	Initiated	Outperform	X
APLS Apellis Pharmaceuticals William Blair
5/31/24	Initiated	Neutral	X
APLS Apellis Pharmaceuticals Piper Sandler
$46
2/5/24	Upgrades	Hold Buy	X
APLS Apellis Pharmaceuticals Jefferies
$68 $80
12/14/23	Downgrades	Overweight Eq Weight	X
APLS Apellis Pharmaceuticals Wells Fargo
11/9/23	Initiated	Buy	X
APLS Apellis Pharmaceuticals Goldman
$74
11/2/23	Initiated	Neutral	X
APLS Apellis Pharmaceuticals Mizuho
$42
10/6/23	Upgrades	Neutral Overweight	X
APLS Apellis Pharmaceuticals JP Morgan
$60 $81
9/15/23	Upgrades	Eq Weight Overweight	X
APLS Apellis Pharmaceuticals Wells Fargo
$34 $64
8/29/23	Reiterated	Buy	X
APLS Apellis Pharmaceuticals Citigroup
$45 $54
8/3/23	Downgrades	Overweight Neutral	X
APLS Apellis Pharmaceuticals JP Morgan
$72 $60
8/1/23	Downgrades	Buy Neutral	X
APLS Apellis Pharmaceuticals BofA Securities
$114 $40
1/3/23	Downgrades	Overweight Eq Weight	X
APLS Apellis Pharmaceuticals Wells Fargo
$83 $58
11/10/22	Downgrades	Buy Hold	X
APLS Apellis Pharmaceuticals Jefferies
$70 $40
7/19/22	Initiated	Buy	X
APLS Apellis Pharmaceuticals H.C. Wainwright
$75
6/17/22	Resumed	Buy	X
APLS Apellis Pharmaceuticals Stifel
$60
4/14/22	Downgrades	Neutral Sell	X
APLS Apellis Pharmaceuticals ROTH Capital
$40
12/8/21	Initiated	Overweight	X
APLS Apellis Pharmaceuticals Wells Fargo
$84
5/21/21	Initiated	Buy	X
APLS Apellis Pharmaceuticals UBS
$82
4/16/21	Initiated	Buy	X
APLS Apellis Pharmaceuticals Goldman
$130
8/1/19	Reiterated	Overweight	X
APLS Apellis Pharmaceuticals Cantor Fitzgerald
$52 $50
7/12/19	Upgrades	Neutral Overweight	X
APLS Apellis Pharmaceuticals JP Morgan
$35 $49
3/29/19	Initiated	Outperform	X
APLS Apellis Pharmaceuticals Robert W. Baird
$45
1/23/19	Downgrades	Overweight Neutral	X
APLS Apellis Pharmaceuticals JP Morgan
7/30/18	Upgrades	Neutral Buy	X
APLS Apellis Pharmaceuticals B. Riley FBR
$27
5/24/18	Initiated	Overweight	X
APLS Apellis Pharmaceuticals Cantor Fitzgerald
$52
4/12/18	Downgrades	Buy Neutral	X
APLS Apellis Pharmaceuticals B. Riley FBR, Inc.
$27
2/8/18	Initiated	Buy	X
APLS Apellis Pharmaceuticals B. Riley FBR, Inc.
$27

APLS Apellis Pharmaceuticals, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.